» Articles » PMID: 33780749

Reinforcing Adherence to Lipid-lowering Therapy After an Acute Coronary Syndrome: A Pragmatic Randomized Controlled Trial

Abstract

Background And Aims: Achieving the low-density lipoprotein cholesterol (LDL-C) goal following an acute coronary syndrome (ACS) is a milestone often missed due to suboptimal adherence to secondary prevention treatments. Whether improved adherence could result in reduced LDL-C levels is unclear. We aimed to evaluate whether an educational-motivational intervention increases long-term lipid-lowering therapy (LLT) adherence and LDL-C goal attainment rate among post-ACS patients.

Methods: IDEAL-LDL was a parallel, two-arm, single-center, pragmatic, investigator-initiated randomized controlled trial. Hospitalized patients for ACS were randomized to a physician-led integrated intervention consisting of an educational session at baseline, followed by regular motivational interviewing phone sessions or usual care. Co-primary outcomes were the LLT adherence (measured by Proportion of Days Covered (PDC); good adherence defined as PDC>80%), and LDL-C goal (<70 mg/dl or 50% reduction from baseline) achievement rate at one year.

Results: In total, 360 patients (mean age 62 years, 81% male) were randomized. Overall, good adherence was positively associated with LDL-C goal achievement rate at one year. Median PDC was higher in the intervention group than the control group [0.92 (IQR, 0.82-1.00) vs. 0.86 (0.62-0.98); p = 0.03] while the intervention group had increased odds of good adherence (odds ratio: 1.76 (95% confidence interval 1.02 to 2.62; p = 0.04). However, neither the LDL-C goal achievement rate (49.6% in the intervention vs. 44.9% in the control group; p = 0.49) nor clinical outcomes differed significantly between the two groups.

Conclusions: Α multifaceted intervention improved LLT adherence in post-ACS patients without a significant difference in LDL-C goal attainment.

Citing Articles

Learnings from Implementation Strategies to Improve Lipid Management.

Lan N, Chen R, Dwivedi G, Watts G, Nicholls S, Nelson A Curr Cardiol Rep. 2025; 27(1):9.

PMID: 39775142 PMC: 11711772. DOI: 10.1007/s11886-024-02174-8.


Effectiveness of treat-to-target cholesterol-lowering interventions on cardiovascular disease and all-cause mortality risk in the community-dwelling population: a target trial emulation.

Yang Z, Deng Q, Hao Y, Yang N, Han L, Jia P Nat Commun. 2024; 15(1):9922.

PMID: 39548082 PMC: 11568141. DOI: 10.1038/s41467-024-54078-4.


Improving transitional care after acute myocardial infarction: A scoping review.

Homem F, Reveles A, Amaral A, Coutinho V, Goncalves L Health Care Sci. 2024; 3(5):312-328.

PMID: 39479273 PMC: 11520247. DOI: 10.1002/hcs2.116.


Association between medication adherence and health-related quality of life of patients with hypertension and dyslipidemia.

Chantzaras A, Yfantopoulos J Hormones (Athens). 2023; 22(4):665-676.

PMID: 37493942 DOI: 10.1007/s42000-023-00471-5.


Prospective evaluation of lipid management following acute coronary syndrome in Saudi Arabia.

Arafah M, Youssef M, AlSamadi F Saudi Med J. 2023; 44(6):570-579.

PMID: 37343983 PMC: 10284230. DOI: 10.15537/smj.2023.44.6.20230023.